Evidence map›Paper›PMID 41193665›Full record

ArticleCommunications chemistry2025

Development and characterisation of novel oxytocin analogues for PET imaging.

Giancarlo Pascali, Arvind Parmar, Simone Zanoni, Andrew Arthur, Anke Hering, Ngari Teakle, Jack Markham, Bo Zhang, Tiffany Mackay, Mitch Klenner and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Giancarlo PascaliAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia. gianp@ansto.gov.au.ORCID http://orcid.org/0000-0001-7919-8416
Arvind ParmarAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia. arvind.parmar@sydney.edu.au.ORCID http://orcid.org/0009-0000-6615-6583
Simone ZanoniSchool of Chemistry, University of New South Wales, Sydney, NSW, Australia.
Andrew ArthurAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.
Anke HeringInstitute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.
Ngari TeakleInstitute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.
Jack MarkhamAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.
Bo ZhangAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.
Tiffany MackayBrain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Mitch KlennerAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.
Lawson SpareAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0003-2036-068X
Ivan GreguricAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.
Amanda McDonaldAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.
Aleksandra BjelosevicAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0003-3036-4756
Lidia MatesicAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.
Gita RahardjoAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.
David ZahraAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.
Hasar HamzeAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.
Ian B HickieBrain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-8832-9895
Richard B BanatiAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.
Marie-Claude GregoireAustralian Nuclear Science and Technology Organisation, Sydney, NSW, Australia.
Larry YoungEmory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-2044-2239
Markus MuttenthalerInstitute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia. markus.muttenthaler@univie.ac.at.ORCID http://orcid.org/0000-0003-1996-4646
Adam J GuastellaBrain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. adam.guastella@sydney.edu.au.ORCID http://orcid.org/0000-0001-8178-4625

Funding

Department of Education and Training | Australian Research Council (ARC) FT210100266Department of Education and Training | Australian Research Council (ARC) LP150101307EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 714366
6 · The paper itself

Abstract

The oxytocin/oxytocin receptor (OT/OTR) signalling system is involved in socioemotional behaviours, garnering interest as a therapeutic target across multiple clinical conditions. Despite its potential, our limited understanding of how to optimally target it and the scarcity of molecular tools for in vivo studies hinder therapeutic development. Molecular imaging techniques, such as Positron Emission Tomography (PET), can bridge this gap by furnishing direct insights into ligand biodistribution, receptor visualisation and ligand-receptor engagement. Here, we report the design, synthesis and biochemical and pharmacological characterisation of five OT-like peptides as novel PET tracers for investigating the OT/OTR signalling system. dOTK

Identifiers

PMID41193665
PMCPMC12589438

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.